Synovial Sarcoma

Postoperatively, the patient received chemotherapy with epirubicin combined with ifosfamide. Follow-up showed no significant evidence of metastasis or recurrence. This report aims to provide clinical reference regarding the imaging findings and diagnosis of this rare disease, primary renal synovial sarcoma.

These CAR-T cells showed effector responses and antitumor effects against synovial sarcoma cells in vitro, as demonstrated by the results of the intracellular cytokine production, cytokine secretion, CD107a degranulation assay, WST-8 assay, and real-time cell analysis, and in vivo in an NSG mouse xenograft model of synovial sarcoma. Although further mechanistic, translational, and safety validation studies are required, these findings provide a preliminary disease-specific preclinical proof of concept for HLA-independent NKG2D-based CAR-T cell therapy in synovial sarcoma, particularly in patients who are ineligible for or have not responded to TCR-T therapy.

In vivo, apatinib markedly suppressed xenograft tumor growth and modulated the corresponding signaling pathways. Collectively, our findings identify apatinib as a promising therapeutic agent that disrupts interconnected survival and angiogenic networks in SS.

P1, N=9, Recruiting, Zelluna Immunotherapy AS

In conclusion, miR-29b-5p may suppresses cancer stemness and aggressiveness in SS to some extent by targeting EP300, with a relatively more pronounced effect in SSX1 cells. Preliminarily these fundings suggest that miR-29b-5p-mediated modulation of EP300 and the TGF-β signaling pathway may provide a potential research data for synovial sarcoma studies.

Synchronous presentation of differentiated thyroid carcinoma and other malignancies in pediatric patients, while rare, poses significant diagnostic and therapeutic challenges. These cases warrant multidisciplinary evaluation and may reflect underlying cancer predisposition, immune dysregulation, or previously unrecognized risk factors.

P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026

Meanwhile, despite recent advances in diagnosis and therapy, SS remains a diagnostic and clinical challenge due to the associated broad anatomical distribution and diverse histological patterns. This review aims to provide a comprehensive update on the clinical, molecular, and pathological features of SS, with emphasis on diagnostic strategies and treatment approaches.

P1, N=15, Recruiting, Valo Therapeutics Oy | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Oct 2026 --> Apr 2027

Complete surgical excision with aortic wall reconstruction under cardiopulmonary bypass was performed. The patient remains disease-free following adjuvant therapy.

The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology...Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe.

P1, N=8, Recruiting, Northwestern University | Not yet recruiting --> Recruiting | Initiation date: Sep 2026 --> Apr 2026